Back to search
FDAFDA · Food and drugs·Recall number D-0506-2019

Diltiazem HCl Extended-Release Capsules, USP 180mg, Packaged in a) 100-count bottles (NDC 0378-5280-01), and b) 500-count bottles (NDC 0378-5280-05), Rx only, Manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV, 26505

Published February 27, 2019 · Recall initiated: February 13, 2019

Summary

FDA records drug Class III recall D-0506-2019, published February 27, 2019 and initiated February 13, 2019. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 8,159 bottles; Lot: Lot #: 3090167, Exp. October 2019. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: High out of specification results obtained during routine stability testing

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Throughout the United States
Lot
Lot #: 3090167, Exp. October 2019
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Diltiazem HCl Extended-Release Capsules, USP 180mg, Packaged in a) 100-count bottles (NDC 0378-5280-01), and b) 500-count bottles (NDC 0378-5280-05), Rx only, Manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV, 26505 recalled?

Yes. FDA published recall D-0506-2019 on February 27, 2019. Reported hazard: Failed Impurities/Degradation Specifications: High out of specification results obtained during routine stability testing

What should I do if I have this product?

Voluntary: Firm initiated · Letter